Gefitinib for the treatment of non-small-cell lung cancer (Q37357287)

19 August 2017

1 reference

title

Gefitinib for the treatment of non-small-cell lung cancer (English)

1 reference

19 August 2017

1 reference

Toyoaki Hida

1

1 reference

19 August 2017

Shizu Ogawa

2

1 reference

19 August 2017

Jang Chul Park

3

1 reference

19 August 2017

Ji Young Park

4

1 reference

19 August 2017

Junichi Shimizu

5

1 reference

19 August 2017

Yoshitsugu Horio

6

1 reference

19 August 2017

Kimihide Yoshida

7

1 reference

19 August 2017

1 January 2009

1 reference

Expert Review of Anticancer Therapy

19 August 2017

1 reference

19 August 2017

9

1 reference

19 August 2017

1

1 reference

19 August 2017

17-35

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

In vitro metabolism of gefitinib in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Cytochrome P450-dependent metabolism of gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Single-dose clinical pharmacokinetic studies of gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Biological and clinical implications of EGFR mutations in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Severe acute interstitial pneumonia and gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.9.1.17

21 January 2018

Identifiers

DOI

10.1586/14737140.9.1.17

1 reference

19 August 2017

1 reference